Get Started
Breast Cancer Curricula
Step 1

Mentor Workshops
Practice-Based Strategies for Managing
Metastatic Breast Cancer Patients
  1. Course List
Featured Speaker(s)
faculty image
William J. Gradishar, MD, FACP
  • Betsy Bramsen Professor of Breast Oncology
  • Director, Maggie Daley Center for Women's
  • Cancer Care
  • Robert H. Lurie Comprehensive Cancer Center
  • Northwestern University Feinberg School of Medicine
  • Chicago, Illinois
  • Approximately 30% of women diagnosed with early-stage breast cancer will go on to develop metastatic breast cancer (MBC). How can oncologists be helped to navigate the complexity of managing MBC?

    This free, online CME/CE program series, linking experts with busy local oncologists, combines didactic and practical case-based presentations into a curriculum that will both engage participants and provide guidance on best management strategies. Join us for a didactic on-demand webcast focusing on strategies for HER2+ disease, HER2- disease, and triple-negative disease; live, interactive case-based audioconferences discussing HER2+ and triple-negative MBC; and podcasts that present highlights of the live audioconferences.
  • Analyze how resistance to anthracyclines and taxanes develops in patients with metastatic breast cancer and alternative treatment interventions that may overcome resistance.
  • Contrast the efficacy and safety of cytotoxic and targeted therapies in patients with metastatic breast cancer to optimize response to treatment.
  • Formulate treatment strategies according to intrinsic breast cancer subtypes for patients with metastatic breast cancer to optimize response to treatment intervention.
  • Assess treatment strategies for patients with triple-negative metastatic breast cancer that combine cytotoxic and targeted therapies to improve response rates.
  • Target Audience

    These CME/CE activities are intended for practicing oncologists, as well as nurses and pharmacists, involved in the management of patients with breast cancer.


    Activity Goal

    The goal of these CME/CE activities is to enable clinicians to apply the latest evidence concerning targeted therapies, PARP inhibitors, and treatments targeting the microtubule to improve outcomes in patients with breast cancer.